1688-P: Novel Oral Apelin Receptor Agonist PSTC1201 for Selective Weight Loss with Muscle Preservation When Combined with Semaglutide in DIO Mice Model
1. 系统已在2025-07-14 10:30:07对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
Z WANG, W LI, L HU, Z ZHU, NA LIU, S YAO…
Diabetes, 2025
diabetesjournals.org
Introduction and Objective: GLP-1R agonists are approved for treating obesity and diabetes, offering benefits like weight loss and blood glucose control. However, they can also cause muscle reduction, impairing physical function, especially in older patients. Preserving lean mass during GLP-1R agonist therapy is an unmet need. Apelin, an endogenous peptide binding to the APJ receptor, regulates energy and muscle metabolism. A Ph1b trial with an oral APJ agonist, azelaprag, showed muscle preservation in elderly subjects. We describe a …
